UNSPSC 51373443: Codeine/guaifenesin/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373443 Codeine/guaifenesin/pseudoephedrine is a Commodity code that captures pharmaceutical products state and local governments procure for emergency response, public health, and clinical supply. The recent opportunities under this code show that state and local buyers are acquiring naloxone (an opioid reversal agent), safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products for distribution through public health agencies, county health departments, and cooperative purchasing networks. Issuing bodies include county health agencies (Seminole County, Florida), state procurement offices (Minnesota Department of Administration), and multistate cooperative purchasing alliances (MMCAP). The scope spans both emergency-response pharmaceuticals and routine OTC supply, with vendors required to meet cGMP and Drug Supply Chain Security Act compliance, maintain authorized wholesaler relationships, and provide competitive tiered pricing structures.

Activity under the code concentrates in Florida and Minnesota, with multistate coverage through cooperative purchasing vehicles. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023 at 2:00 pm and a two-year initial contract term with one-year renewal option. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 through MMCAP on January 20, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with a March 26, 2026 proposal deadline and July 1, 2026 contract effective date; the evaluation weighting heavily emphasizes price competitiveness at 75 percent, with contract terms of two years for new vendors and alignment through June 30, 2028 for incumbents.